EFV | NVP | |||
---|---|---|---|---|
At 24 weeks | At 48 weeks | At 24 weeks | At 48 weeks | |
Patients (n) | 28 (26.0%) | 52 (52.0%) | 12 (14.2%) | 48 (60%) |
Cumulative incidence | 0.3 | 0.6 | 0.2 | 0.8 |
Relative Risk | 1.7 | 0.8 | 0.5 | 1.2 |
% relative effect | 75.0% increase | 18.7% decrease | 43.0% decrease | 23.0% increase |